Chromatography Media Quality Evaluation Using Purified IgM Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the quality of chromatography media containing blood group A or B antigen ligands lack efficiency and reproducibility, making it challenging to ensure consistent removal of anti-A and anti-B antibodies from blood-derived products, which can lead to hemolytic reactions in recipients.
Innovation Solution
A method involving the use of purified monoclonal IgM antibodies to assess the static binding capacity of chromatography media, allowing for comparison of different media samples and evaluation of their ability to remove anti-A or anti-B antibodies, using the equation [C1-C2] × VM / VR, where C1 and C2 are antibody concentrations before and after binding, and VM and VR are solution and media volumes respectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional methods are used to evaluate chromatography media quality, then the evaluation process can be performed, but the method lacks efficiency and reproducibility
Solution Approach 1:
The patent changes the evaluation parameter from traditional complex assays to a simplified binding capacity measurement using purified IgM antibodies. By measuring the binding capacity (CB) through a straightforward calculation based on antibody concentrations before and after binding, the method achieves both high reproducibility and efficiency, resolving the contradiction between reliable evaluation and operational efficiency
2Productivity
If chromatography media is used to remove anti-A or anti-B antibodies from pooled plasma, then blood-derived products can be produced, but there is risk of hemolytic reactions in recipients
Solution Approach 1:
The patent implements a feedback mechanism by evaluating the binding capacity of chromatography media batches before use. By measuring CB values and comparing them against established ranges, the system provides feedback on media quality, enabling selection of appropriate media batches that will effectively remove anti-A or anti-B antibodies, thus preventing hemolytic reactions while maintaining product production
Solution Approach 2:
The patent performs preliminary evaluation of chromatography media binding capacity before the actual antibody removal process. By assessing CB values in advance and establishing acceptable ranges, the system prepares and validates media batches beforehand, ensuring they are suitable for removing harmful antibodies from blood-derived products, thereby preventing hemolytic reactions in recipients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more efficient and reproducible method to assess the quality of chromatography media, correlating IgM binding capacity with the ability to remove anti-A or anti-B antibodies, thereby ensuring the reliability and safety of blood-derived products.
Implementation Method 1
chromatography media containing blood group A antigen ligand or blood group B antigen ligand attached to a solid support
Data Source
AI summary
Embodiments described herein relate to methods of evaluating quality of a chromatography media for removal of anti-A or anti-B antibodies from a sample, where the methods employ use of purified monoclonal IgM-A and IgM-B antibodies.